1. Home
  2. VLTO vs INSM Comparison

VLTO vs INSM Comparison

Compare VLTO & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veralto Corp

VLTO

Veralto Corp

HOLD

Current Price

$97.20

Market Cap

24.0B

Sector

Industrials

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$117.34

Market Cap

22.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VLTO
INSM
Founded
2023
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.0B
22.4B
IPO Year
2023
2000

Fundamental Metrics

Financial Performance
Metric
VLTO
INSM
Price
$97.20
$117.34
Analyst Decision
Buy
Strong Buy
Analyst Count
11
24
Target Price
$108.90
★ $201.17
AVG Volume (30 Days)
1.3M
★ 1.8M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
★ 0.58%
N/A
EPS Growth
★ 12.57
N/A
EPS
★ 1.02
N/A
Revenue
★ $5,503,000,000.00
N/A
Revenue This Year
$8.52
$182.31
Revenue Next Year
$5.26
$65.19
P/E Ratio
$94.31
★ N/A
Revenue Growth
★ 5.97
N/A
52 Week Low
$80.03
$90.39
52 Week High
$107.90
$212.75

Technical Indicators

Market Signals
Indicator
VLTO
INSM
Relative Strength Index (RSI) 55.02 43.80
Support Level $95.76 $97.66
Resistance Level $97.38 $119.54
Average True Range (ATR) 1.46 5.39
MACD 0.07 -1.04
Stochastic Oscillator 89.15 11.63

Price Performance

Historical Comparison
VLTO
INSM

About VLTO Veralto Corp

Veralto is a diversified industrial firm organized into two segments. The water quality segment offers water analytics and water treatment solutions, while the product quality and innovation segment offers coding, packaging, and color solutions for consumer packaged goods and pharmaceuticals. Headquartered in Waltham, Massachusetts, the company has around 17,000 employees. Veralto generated approximately $5.5 billion in revenue in 2025.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: